Correlation Between SAB Biotherapeutics and Ultragenyx
Can any of the company-specific risk be diversified away by investing in both SAB Biotherapeutics and Ultragenyx at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining SAB Biotherapeutics and Ultragenyx into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between SAB Biotherapeutics and Ultragenyx, you can compare the effects of market volatilities on SAB Biotherapeutics and Ultragenyx and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in SAB Biotherapeutics with a short position of Ultragenyx. Check out your portfolio center. Please also check ongoing floating volatility patterns of SAB Biotherapeutics and Ultragenyx.
Diversification Opportunities for SAB Biotherapeutics and Ultragenyx
-0.74 | Correlation Coefficient |
Pay attention - limited upside
The 3 months correlation between SAB and Ultragenyx is -0.74. Overlapping area represents the amount of risk that can be diversified away by holding SAB Biotherapeutics and Ultragenyx in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Ultragenyx and SAB Biotherapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on SAB Biotherapeutics are associated (or correlated) with Ultragenyx. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Ultragenyx has no effect on the direction of SAB Biotherapeutics i.e., SAB Biotherapeutics and Ultragenyx go up and down completely randomly.
Pair Corralation between SAB Biotherapeutics and Ultragenyx
Assuming the 90 days horizon SAB Biotherapeutics is expected to generate 9.99 times more return on investment than Ultragenyx. However, SAB Biotherapeutics is 9.99 times more volatile than Ultragenyx. It trades about 0.17 of its potential returns per unit of risk. Ultragenyx is currently generating about -0.22 per unit of risk. If you would invest 5.00 in SAB Biotherapeutics on August 28, 2024 and sell it today you would earn a total of 1.88 from holding SAB Biotherapeutics or generate 37.6% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Weak |
| Accuracy | 85.71% |
| Values | Daily Returns |
SAB Biotherapeutics vs. Ultragenyx
Performance |
| Timeline |
| SAB Biotherapeutics |
| Ultragenyx |
SAB Biotherapeutics and Ultragenyx Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with SAB Biotherapeutics and Ultragenyx
The main advantage of trading using opposite SAB Biotherapeutics and Ultragenyx positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if SAB Biotherapeutics position performs unexpectedly, Ultragenyx can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ultragenyx will offset losses from the drop in Ultragenyx's long position.| SAB Biotherapeutics vs. SAB Biotherapeutics | SAB Biotherapeutics vs. Jasper Therapeutics | SAB Biotherapeutics vs. NRx Pharmaceuticals |
| Ultragenyx vs. X4 Pharmaceuticals | Ultragenyx vs. Terns Pharmaceuticals | Ultragenyx vs. Day One Biopharmaceuticals | Ultragenyx vs. PDS Biotechnology Corp |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Other Complementary Tools
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |